Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Timing of antiretroviral therapy initiation and its impact on disease progression in perinatal human immunodeficiency virus-1 infection.

Sturt AS, Halpern MS, Sullivan B, Maldonado YA.

Pediatr Infect Dis J. 2012 Jan;31(1):53-60. doi: 10.1097/INF.0b013e31823515a2.

2.

Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.

Sánchez JM, Ramos Amador JT, Fernández de Miguel S, González Tomée MI, Rojo Conejo P, Ferrnado Vivas P, Clemente Vivas J, Ruiz Contreras J, Nogales Espert A.

Pediatr Infect Dis J. 2003 Oct;22(10):863-7.

PMID:
14551485
3.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
4.

Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort.

Berk DR, Falkovitz-Halpern MS, Hill DW, Albin C, Arrieta A, Bork JM, Cohan D, Nilson B, Petru A, Ruiz J, Weintrub PS, Wenman W, Maldonado YA; California Pediatric HIV Study Group.

JAMA. 2005 May 11;293(18):2221-31.

PMID:
15886377
5.

Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy.

Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjananit S, Wannarit P, Sirisanthana T, Sirisanthana V.

Clin Infect Dis. 2007 Feb 15;44(4):599-604. Epub 2007 Jan 9.

6.
7.

Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.

Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, Novelli V, Lyall EG, Masters J, Tudor-Williams G, Duong T, Gibb DM; Collaborative HIV Paediatric Study (CHIPS); National Study of HIV in Pregnancy and Childhood (NSHPC).

Clin Infect Dis. 2007 Oct 1;45(7):918-24. Epub 2007 Aug 27.

8.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

9.
10.

Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR 3rd; Pediatric AIDS Clincial Trials Group Protocol 219C Team.

Arch Pediatr Adolesc Med. 2006 Aug;160(8):778-87.

PMID:
16894075
11.

Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10).

Dollfus C, Le Chenadec J, Faye A, Blanche S, Briand N, Rouzioux C, Warszawski J.

Clin Infect Dis. 2010 Jul 15;51(2):214-24. doi: 10.1086/653674.

12.

Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort.

Wamalwa DC, Obimbo EM, Farquhar C, Richardson BA, Mbori-Ngacha DA, Inwani I, Benki-Nugent S, John-Stewart G.

BMC Pediatr. 2010 May 18;10:33. doi: 10.1186/1471-2431-10-33.

13.

Initial experience of a public sector antiretroviral treatment programme for HIV-infected children and their infected parents.

Eley B, Nuttall J, Davies MA, Smith L, Cowburn C, Buys H, Hussey G.

S Afr Med J. 2004 Aug;94(8):643-6.

PMID:
15352588
14.

CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation?

Newell ML, Patel D, Goetghebuer T, Thorne C; European Collaborative Study.

J Infect Dis. 2006 Apr 1;193(7):954-62. Epub 2006 Feb 23.

15.

Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).

Kapogiannis BG, Soe MM, Nesheim SR, Abrams EJ, Carter RJ, Farley J, Palumbo P, Koenig LJ, Bulterys M.

Clin Infect Dis. 2011 Nov;53(10):1024-34. doi: 10.1093/cid/cir641.

16.

Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life.

Gray L, Newell ML, Thorne C, Peckham C, Levy J; European Collaborative Study.

Pediatrics. 2001 Jul;108(1):116-22.

PMID:
11433063
17.

Maternal outcomes after HAART for the prevention of mother-to-child transmission in HIV-infected women in Brazil.

Pilotto JH, Velasque LS, Friedman RK, Moreira RI, Veloso VG, Grinsztejn B, Morgado MG, Watts DH, Currier JS, Hoffman RM.

Antivir Ther. 2011;16(3):349-56. doi: 10.3851/IMP1779.

18.

Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.

Resino S, Resino R, Micheloud D, Gurbindo Gutiérrez D, Léon JA, Ramos JT, Ciria L, de José I, Mellado J, Muñoz-Fernández A; Spanish Group of Paediatric HIV Infection.

Clin Infect Dis. 2006 Mar 15;42(6):862-9. Epub 2006 Feb 9.

19.

Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.

Oliveira R, Krauss M, Essama-Bibi S, Hofer C, Robert Harris D, Tiraboschi A, de Souza R, Marques H, Succi R, Abreu T, Della Negra M, Hazra R, Mofenson LM, Siberry GK; NISDI Pediatric Study Group 2010.

Clin Infect Dis. 2010 Dec 1;51(11):1325-33. doi: 10.1086/657119. Epub 2010 Nov 1.

20.

The impact of highly active antiretroviral therapy on the survival of vertically HIV-infected children and adolescents in Belo Horizonte, Brazil.

Cardoso CA, Pinto JA, Candiani TM, Carvalho IR, Linhares RM, Goulart EM.

Mem Inst Oswaldo Cruz. 2012 Jun;107(4):532-8.

Items per page

Supplemental Content

Write to the Help Desk